Bioforum Signs Exclusive Deal to Acquire Assets from Abond CRO Inc., Expanding Reach of Global Biometric Services



Abond Selects Bioforum to Deliver Continuity of Statistical Analysis and Data Management Support Services to Clinical Trial Sponsor Clients Worldwide

US-Based Biotechs Transition from Abond to Bioforum to Drive Clinical Trial Efficiency and Optimization 

NESS ZIONA, Israel, Feb. 20, 2024 /PRNewswire/ — Bioforum, the Data Masters, a leading contract research organization (CRO) focused on the delivery of biometric services and solutions to clinical trial sponsors worldwide, today announced that it has been exclusively selected by Abond CRO Inc., a full-service CRO that ceased operations in December 2023, to provide business continuity services to its biopharmaceutical and medical device customers around the globe. Under the terms of the agreement, Abond customers will have the opportunity to seamlessly transition to Bioforum and receive best-in-class data management and statistical analysis services to drive clinical trial efficiency. 

Several US-based biotechs and long-term Abond clients recently signed agreements with Bioforum. These biotechs and other former Abond customers who transition to Bioforum will also have access to a range of industry-leading, technology-enabled solutions the Company has developed to address critical gaps in data management and drive automation of key study processes, such as tools for visual analytics (BioGrid), SDTM conversation (JetConvert), and risk analysis and validation (

Full story available on


Leave a Reply

Your email address will not be published. Required fields are marked *